Consistently, blocking B7-H4 in breast cancer is synergistic with PD-1 blockage [30], trastuzumab treatment [31], and doxorubicin, paclitaxel, and carboplatin [29], suggesting it is widely involved in resistance to anti-cancer therapies. The gene discussed is VTCN1; the disease is breast carcinoma.